Argument & Sources

Should access to GLP-1 weight-loss drugs be publicly reimbursed?

Public coverage for semaglutide and similar treatments.

14 votes|10 arguments|0 source

36%5

3/5 Arguments

Reimbursement should wait for long-term safety data on muscle mass loss, pancreatitis and thyroid risk in non-diabetic patients. @@no_3

Systematic review of semaglutide and tirzepatide trials and a cost-effectiveness model for public reimbursement.